Nektar Therapeutics (NKTR) Director Christopher A. Kuebler Sells 7,500 Shares
Nektar Therapeutics (NASDAQ:NKTR) Director Christopher A. Kuebler sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $19.13, for a total transaction of $143,475.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at 18.97 on Wednesday. Nektar Therapeutics has a 52-week low of $9.92 and a 52-week high of $19.98. The firm’s market capitalization is $2.59 billion. The company’s 50-day moving average is $18.04 and its 200 day moving average is $15.47.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.03. Nektar Therapeutics had a negative net margin of 68.30% and a negative return on equity of 8,769.15%. The firm earned $32.77 million during the quarter, compared to the consensus estimate of $34.17 million. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. The company’s revenue was up 44.6% on a year-over-year basis. Analysts expect that Nektar Therapeutics will post ($1.11) EPS for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/nektar-therapeutics-nktr-director-christopher-a-kuebler-sells-7500-shares.html
Large investors have recently made changes to their positions in the stock. Primecap Management Co. CA boosted its stake in shares of Nektar Therapeutics by 1.1% in the first quarter. Primecap Management Co. CA now owns 20,010,086 shares of the biopharmaceutical company’s stock valued at $275,139,000 after buying an additional 225,800 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Nektar Therapeutics by 2.7% in the second quarter. Vanguard Group Inc. now owns 11,650,468 shares of the biopharmaceutical company’s stock valued at $165,787,000 after buying an additional 301,245 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Nektar Therapeutics by 1.9% in the second quarter. BlackRock Fund Advisors now owns 10,221,478 shares of the biopharmaceutical company’s stock valued at $145,452,000 after buying an additional 192,003 shares in the last quarter. Bridger Management LLC bought a new stake in shares of Nektar Therapeutics during the first quarter valued at $48,359,000. Finally, State Street Corp boosted its stake in shares of Nektar Therapeutics by 4.5% in the first quarter. State Street Corp now owns 3,480,120 shares of the biopharmaceutical company’s stock valued at $47,852,000 after buying an additional 151,371 shares in the last quarter. Hedge funds and other institutional investors own 96.91% of the company’s stock.
A number of equities research analysts have recently weighed in on NKTR shares. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price target on the stock in a research note on Tuesday, July 19th. Jefferies Group reiterated a “buy” rating on shares of Nektar Therapeutics in a research report on Thursday, September 8th. Brean Capital reiterated a “buy” rating and set a $18.00 target price on shares of Nektar Therapeutics in a research report on Friday, August 5th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $21.00 target price (up from $17.00) on shares of Nektar Therapeutics in a research report on Friday, August 5th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.50.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.